Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06698926 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 110
- Enrollment target
NCT06698926 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 110 participants.
The verdict
NCT06698926, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 110 participants
- Enrollment target
Study Summary
This is a Phase 1, first in human, randomized, four-part study to investigate the safety, tolerability, and pharmacokinetics of ABBV-CLS-616 after oral dosing in healthy volunteers.
Interventions
- DRUG Placebo
- DRUG Itraconazole
- DRUG ABBV-CLS-616
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2024-11-11 |
| Est. Completion | 2026-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06698926
The ClinicalTrials.gov registry entry for NCT06698926 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06698926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06698926 about?
NCT06698926 is a clinical study titled "A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants". This is a Phase 1, first in human, randomized, four-part study to investigate the safety, tolerability, and pharmacokinetics of ABBV-CLS-616 after oral dosing in healthy volunteers.
What is the current status of trial NCT06698926?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 110 participants. The study started on 2024-11-11. Estimated completion is 2026-01-09.
What interventions are being tested in trial NCT06698926?
The interventions under investigation include: Placebo (DRUG), Itraconazole (DRUG), ABBV-CLS-616 (DRUG).
Who is sponsoring clinical trial NCT06698926?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.